Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol - PubMed (original) (raw)

PMID: 6530619
DOI: 10.1007/BF00178114

Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol

D J Stewart et al. J Neurooncol. 1984.

Abstract

Thirty-four consenting patients received VM-26 50-100 mg/m2 I.V. before surgical resection of intracerebral tumor, and drug was measured using a high pressure liquid chromatographic technique. Sufficient tumor for analysis was obtained from 29 patients. Brain metastases (13 patients) had higher concentrations of VM-26 than did gliomas (13 patients). Concentrations were comparable in brain metastases and meningiomas (3 patients). Prolonged (24 h) infusion of VM-26 did not appear to result in higher tumor drug concentrations in 5 patients than did rapid (1 h) infusion in 24 patients. Pretreatment with Amphotericin-B 10 mg/m2 12 h and 1 h before VM-26 did not appear to have any effect on VM-26 uptake into 4 intracerebral tumors, although data were limited, and VM-26 concentrations were very high in 1 metastasis. Pretreatment with oral glycerol 500 mg/kg 18 h, 12 h, 6 h, and immediately before I.V. VM-26 may have resulted in increased penetration of VM-26 into 9 tumors, although confirmation is required. Amphotericin-B, glycerol, and operative conditions did not appear to alter VM-26 plasma pharmacokinetics.

PubMed Disclaimer

Cited by

Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies.
Stewart DJ, Maroun JA, Hugenholtz H, Benoit B, Girard A, Richard M, Russell N, Huebsch L, Drouin J. Stewart DJ, et al. J Neurooncol. 1987;5(4):315-22. doi: 10.1007/BF00148388. J Neurooncol. 1987. PMID: 3126273
Pharmacokinetics of anticancer drugs in children.
Crom WR, Glynn-Barnhart AM, Rodman JH, Teresi ME, Kavanagh RE, Christensen ML, Relling MV, Evans WE. Crom WR, et al. Clin Pharmacokinet. 1987 Mar;12(3):168-213. doi: 10.2165/00003088-198712030-00002. Clin Pharmacokinet. 1987. PMID: 3555940 Review.
Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.
Stewart DJ, Grahovac Z, Hugenholtz H, DaSilva V, Richard MT, Benoit B, Belanger G, Russell N. Stewart DJ, et al. J Neurooncol. 1993 Jul;17(1):71-9. doi: 10.1007/BF01054276. J Neurooncol. 1993. PMID: 8120574 Clinical Trial.
Tissue concentration of systemically administered antineoplastic agents in human brain tumors.
Pitz MW, Desai A, Grossman SA, Blakeley JO. Pitz MW, et al. J Neurooncol. 2011 Sep;104(3):629-38. doi: 10.1007/s11060-011-0564-y. Epub 2011 Mar 12. J Neurooncol. 2011. PMID: 21400119 Free PMC article. Review.
Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.
Holthuis JJ. Holthuis JJ. Pharm Weekbl Sci. 1988 Jun 17;10(3):101-16. doi: 10.1007/BF01959294. Pharm Weekbl Sci. 1988. PMID: 3047665 Review.

References

1. Cancer Res. 1979 Oct;39(10):4119-22 - PubMed
1. Clin Pharmacol Ther. 1975 Aug;18(2):227-33 - PubMed
1. Cancer. 1974 Feb;33(2):460-7 - PubMed
1. Arch Neurol. 1975 Dec;32(12):785-91 - PubMed
1. J Neurooncol. 1983;1(1):15-9 - PubMed

Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol - PubMed (original) (raw)